Phio Pharmaceuticals Corp. (44R1)
XMUN 
Summary
44R1 Chart
Phio Pharmaceuticals Corp. Dividends
Phio Pharmaceuticals Corp. Earnings
| 7 May 2025 (17 Days) Date | | - Cons. EPS | - EPS |
| 31 Mar 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2024 Date | | - Cons. EPS | - EPS |
| 9 Aug 2024 Date | | - Cons. EPS | - EPS |
| 7 May 2025 (17 Days) Date | | - Cons. EPS | - EPS |
| 31 Mar 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2024 Date | | - Cons. EPS | - EPS |
| 9 Aug 2024 Date | | - Cons. EPS | - EPS |
Phio Pharmaceuticals Corp. (44R1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Phio Pharmaceuticals Corp. ever had a stock split?
Phio Pharmaceuticals Corp. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Robert J. Bitterman CEO | XMUN Exchange | US71880W3034 ISIN |
| US Country | 8 Employees | - Last Dividend | 5 Jul 2024 Last Split | 10 May 2012 IPO Date |
Overview
Phio Pharmaceuticals Corp. is a pioneering entity in the field of immuno-oncology therapeutics within the United States, focusing on the development of innovative treatments designed to enhance the immune system's ability to fight cancer. Initially known as RXi Pharmaceuticals Corporation, the company underwent a name change to Phio Pharmaceuticals Corp. in November 2018, marking a new chapter in its mission to advance cancer treatment options. Incorporated in 2011 and based out of Marlborough, Massachusetts, Phio Pharmaceuticals Corp. is at the forefront of leveraging genetic insights and cutting-edge technology to develop therapies that target and suppress the mechanisms cancer cells use to evade the immune system.
Products and Services
Phio Pharmaceuticals Corp.'s research and development efforts have yielded a promising portfolio of INTASYL compounds, each designed to silence genes that play critical roles in the suppression of the immune response to cancer. These compounds include:
- PH-762: This compound is aimed at reducing the expression of the Cell Death Protein 1 (PD-1). PD-1 is a protein that inhibits the ability of T cells, a crucial component of the immune system, to kill cancer cells. By targeting PD-1, PH-762 seeks to enhance the immune system's capacity to fight off cancer.
- PH-894: PH-894 focuses on silencing the BRD4 gene, a significant player in controlling gene expression within both T cells and tumor cells. By targeting BRD4, this compound not only affects the immune system's effectiveness but also directly impacts tumor growth and proliferation, making it a dual-action therapy with the potential to significantly disrupt cancer progression.
- PH-804: This compound targets TIGIT, a protein that inhibits the activity of Natural Killer (NK) cells, which are part of the body's first line of defense against cancer. By silencing TIGIT, PH-804 aims to unleash the full potential of NK cells against cancer cells, offering a promising strategy to boost the body's natural immune response to tumors.
Contact Information
